Although CD26/DPPIV function in cancer biology is not yet fully characterized, CD26 serves as a prognostic marker in multiple tumors such as CRC, GIST, thyroid carcinoma, urothelial carcinoma and prostate cancer [10–14]. This evidence concerns the gene DPP4 and gastrointestinal stromal tumor.